These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 18711346)

  • 1. 400 cGy TBI with fludarabine for reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.
    Sobecks RM; Dean R; Rybicki LA; Chan J; Theil KS; Macklis R; Andresen S; Kalaycio M; Pohlman B; Ferraro C; Cherni K; Sweetenham J; Copelan E; Bolwell BJ
    Bone Marrow Transplant; 2008 Dec; 42(11):715-22. PubMed ID: 18711346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
    Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
    Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
    Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
    Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-intensity conditioning using fludarabine with either antithymocyte globulin and BU, or low-dose TBI allowing allogeneic hematopoietic SCT.
    Cable C; Buzzeo MP; Schold JD; Khan S; Leather H; Moreb J; Jamieson K; Scornik J; Amdur RJ; Wingard JR; Reddy V
    Bone Marrow Transplant; 2010 Jan; 45(1):31-7. PubMed ID: 19543325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
    van Besien K; Devine S; Wickrema A; Jessop E; Amin K; Yassine M; Maynard V; Stock W; Peace D; Ravandi F; Chen YH; Cheung T; Vijayakumar S; Hoffman R; Sosman J
    Bone Marrow Transplant; 2003 Jul; 32(1):9-13. PubMed ID: 12815472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
    Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
    Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unrelated donor hematopoietic stem cell transplantation for patients with hematologic malignancies using a nonmyeloablative conditioning regimen of fludarabine, low-dose total body irradiation, and rabbit antithymocyte globulin.
    Rowley SD; Goldberg SL; Pecora AL; Hsu JS; Brecher BA; Butrin L; Kobbe K; McKiernan P; Preti R
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):784-93. PubMed ID: 15505609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unrelated umbilical cord blood transplantation using a TBI/FLAG conditioning regimen for adults with hematologic malignancies.
    Okada M; Fujimori Y; Misawa M; Kai S; Nakajima T; Okikawa Y; Satake A; Itoi H; Takatsuka H; Itsukuma T; Nishioka K; Tamaki H; Ikegame K; Hara H; Ogawa H
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):896-903. PubMed ID: 18640573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.
    Grigg AP; Gibson J; Bardy PG; Reynolds J; Shuttleworth P; Koelmeyer RL; Szer J; Roberts AW; To LB; Kennedy G; Bradstock KF
    Biol Blood Marrow Transplant; 2007 May; 13(5):560-7. PubMed ID: 17448915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed chimerism and graft failure following conditioning with the fludarabine and cyclophosphamide nonablative regimen; conversion to full donor chimerism.
    Jillella AP; Shafer D; Klumpp TR; Emmons RV; Mangan KF
    Am J Hematol; 2007 Jun; 82(6):419-26. PubMed ID: 17211845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced intensity preparative regimens for allogeneic hematopoietic stem cell transplantation: a single center experience.
    Basara N; Roemer E; Kraut L; Guenzelmann S; Schmetzer B; Kiehl MG; Fauser AA
    Bone Marrow Transplant; 2002 Nov; 30(10):651-9. PubMed ID: 12420203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Allogeneic hematopoietic stem cell transplantation following reduced intensity conditioning regimen for treatment of refractory leukemia].
    Jiang JL; Yan SK; Yang J; Cai Y; Wan LP; Qin YW; Wang C
    Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):517-21. PubMed ID: 19112913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.